OFFICIALS LEGISLATION INTEREST GROUPS PUBLIC STATEMENTS COMMITTEES VETOES

National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2020

Floor Speech

Date: Sept. 21, 2020
Location: Washington, DC

BREAK IN TRANSCRIPT

Mr. GUTHRIE. Mr. Speaker, I rise today in support of H.R. 4866, the National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act, a bill I introduced with my colleague, Energy and Commerce Committee Chairman Frank Pallone.

In 2016, I was proud to work with my fellow committee members on the 21st Century Cures Act, which included legislation to issue grants for institutions of higher education to study the process of continuous pharmaceutical manufacturing. H.R. 4866, which we are considering today, builds on this partnership established in the Cures Act.

Continuous manufacturing for pharmaceuticals is a new technology that allows for drugs to be produced in a continuous stream, helping drugs get into the market faster. This is something that has become increasingly important during the COVID-19 pandemic. We need to ensure that our drug supply chain does not depend too heavily on other countries, such as China.

Mr. Speaker, I urge my colleagues to support H.R. 4866.

BREAK IN TRANSCRIPT


Source
arrow_upward